What is IgVH and why is it important? By Susan Leclair DNA within a cell is made up of a ladder of two long strings of many deoxyribose molecules... September 20, 2018Beyond The BasicsBy Brad Hedrick
Ibrutinib’s Approval History and Its Use as Frontline Therapy for CLL Ibrutinib is now approved in the USA for all indications for chronic lymphocytic leukemia. That hasn’t always been the case.... August 13, 2018TreatmentBy Brad Hedrick
CLL Markers and What They Mean: A Patient Perspective – Part II – NOTCH1 By Wayne “WWW” Wells - patient Admittedly this essay is a rabbit-hole in the exploration of CLL biology for which you... June 28, 2018Advanced PrognosticsBy clladm1n
CLL Markers and What They Mean – A Patient Perspective – Part I – ZAP-70 By Wayne “WWW” Wells - patient Most patients with CLL/SLL who have been around for awhile will become aware of the... March 28, 2018Advanced PrognosticsBy clladm1n
Atrial Fibrillation and Ibrutinib in Chronic Lymphocytic Leukemia (CLL) This is a website about hematology, specifically chronic lymphocytic leukemia, but this article will update research on a significant cardiac... February 13, 2018TreatmentBy Todd Dennison
The Role of Radiology and Imaging in Chronic Lymphocytic Leukemia By Chau Huynh, MD The abnormal white blood cells or “leukemic cells” produced in chronic lymphocytic leukemia (CLL) can reside... December 28, 2017What About CT Scans?By clladm1n
CAR-T Therapy Gone Very Bad- What We Can Learn from the Rocket Trial and How it Relates to CLL In 2016, five patients died from complications of CAR-T (Chimeric Antigen Receptors T cell) therapy in JUNO’s Rocket trial. JUNO, to... November 29, 2017Using T-Cells to Fight CLLBy Todd Dennison
Cirmtuzumab: What’s all the ROR-ing about? By Michael Choi, MD The holy grail of cancer therapy research is to make a treatment that can distinguish between... September 27, 2017TreatmentBy clladm1n
Hope For Patients Who Discontinue Ibrutinib or Idelalisib By Anthony R Mato, MD There is little question that the approval of kinase inhibitor therapies such as ibrutinib have... September 19, 2017TreatmentBy clladm1n
No CLL Knockout Punch The more formal title should be: Randomized phase II results – lenalidomide is not a viable option post-allogeneic stem cell... August 29, 2017News, TreatmentBy Todd Dennison
